| Literature DB >> 28725008 |
Mohammad Hassan Baig1, Arif Tasleem Jan1, Gulam Rabbani1, Khurshid Ahmad1, Jalaluddin M Ashraf1,2, Taeyeon Kim1, Han Sol Min3, Yong Ho Lee3, Won-Kyung Cho4, Jin Yeul Ma4, Eun Ju Lee5, Inho Choi6.
Abstract
Methylglyoxal (MG) is a reactive dicarbonyl intermediate and a precursor of advanced glycation end products (AGEs). The authors investigated the role played by AGEs in muscle myopathy and the amelioration of its effects by curcumin and gingerol. In addition to producing phenotypical changes, MG increased oxidative stress and reduced myotube formation in C2C12 cells. RAGE (receptor for AGEs) expression was up-regulated and MYOD and myogenin (MYOG) expressions were concomitantly down-regulated in MG-treated cells. Interestingly, AGE levels were higher in plasma (~32 fold) and muscle (~26 fold) of diabetic mice than in control mice. RAGE knock-down (RAGEkd) reduced the expressions of MYOD and MYOG and myotube formation in C2C12 cells. In silico studies of interactions between curcumin or gingerol and myostatin (MSTN; an inhibitor of myogenesis) and their observed affinities for activin receptor type IIB (ACVRIIB) suggested curcumin and gingerol reduce the interaction between MSTN and ACVRIIB. The findings of this study suggest enhanced AGE production and subsequent RAGE-AGE interaction obstruct the muscle development program, and that curcumin and gingerol attenuate the effect of AGEs on myoblasts.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28725008 PMCID: PMC5517486 DOI: 10.1038/s41598-017-06067-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Association between MG induced AGE production and myogenesis. (A) Cell proliferation in the presence of different concentrations of MG at Day 4. (B) Cells were cultured with or without 200 µM MG for 4 days in differentiation media and ROS levels were assessed using DCFDA by florescence microscopy (n = 3) (C) AGE levels after treatment with 200 µM MG in differentiation media for 0, 2, 4, or 6 days [(−): MG non-treated cells, (+): MG treated cells] (D) Myotube formation and fusion indices of cells treated with or without 200 µM MG for 4 days in differentiation media (E) MYOD, MYOG and RAGE expressions determined by real time PCR and Western blot (n = 3).
Figure 2AGE levels in diabetic and non-diabetic C57BL/6 mice. Levels of AGEs in diabetic and non-diabetic mice (A) Muscle and Plasma (n = 3, P < 0.05). (B) RAGE expression as analyzed by real time PCR and Western blot in cells treated with 200 µM MG for 4 days in differentiation media. (C and D) Effect of insulin supplementation on cell differentiation and RAGE expression as determined by real time PCR and Western blot (n = 3).
Figure 3RAGE gene expression and the effects of its knock-down during differentiation. RAGE knock-down in C2C12 cells (A) Effect of RAGE knock-down on differentiation as determined by myotube formation and by using fusion indices. (B) RAGE, MYOD, and MYOG expressions in RAGEkd cells were determined by real time PCR and Western blot (n = 3).
Figure 4Effect of curcumin and gingerol on cellular differentiation. (A) Cell proliferations in the presence of different concentrations of curcumin (1 or 5 µM) or gingerol (5 or 25 µM). (B) Effects of curcumin or gingerol on myotube formation and fusion indices. (C and D) MYOD and MYOG expression determination by real time PCR and Western blot after treating cells with different concentrations of curcumin or gingerol (n = 3).
Binding scores of selected natural compounds and the residues involved in their interaction with MSTN.
| Compound | Gold fitness score | X-score | Residues involved | |
|---|---|---|---|---|
| Hydrogen bond | Hydrophobic interaction | |||
| Curcumin | 40.15 | −6.86 | T77, R105 | R14, F51, L52, Q53, K54, T77, R105, G107 |
| Gingerol | 40.48 | −6.47 | L52, QQ53, R105 | F22, R14, F51, L52, Q53, T77, R105 |
Figure 5Interactions between curcumin or gingerol with myostatin and their effects on ACVRIIB. (A) Residual interaction between curcumin and MSTN in MSTN-curcumin complex (B) Interaction between ACVRIIB and MSTN-curcumin complex (C) Residual interaction between ACVRIIB and MSTN-curcumin complex (D) Residual interaction between gingerol and MSTN in MSTN-gingerol complex (E) Interaction between ACVRIIB and MSTN-gingerol complex (F) Residual interaction between ACVRIIB and MSTN-gingerol complex.
Residues involved in the binding of MSTN (in the presence of curcumin and gingerol) to its receptor ACVRIIB.
| Complex | Residues involved | |||
|---|---|---|---|---|
| Hydrogen bonding | Hydrophobic interaction | |||
| ACVRIIB | MSTN | ACVRIIB | MSTN | |
| ACVRIIB-MSTN (Curcumin) | R256, D261, G291, C292, R296 | F27, W31, C73, C74, T75 | R115, S118, K253, K254, M255, R256, T258, I259, D261, V274, E277, W280, D281, D283, E285, A286, G291, C292, E294, E295, R296 | L20, A26, F27, G28, W29, W31, Y42, G68, A70, C73, C74, T75, P76, Y86, F87, A100, S109 |
| ACVRIIB-MSTN (Gingerol) | H60, L63, K89, S150, D223 | H57, Y55, P76, S109, G89 | D31, F32, K59, H60, E61, L63, L64, Q65, G66, I67, T84, A85, F86, H87, D88, K89, N99, I100, L148, K149, S150, D151, D223 | Q53, K54, Y55, P56, H57, L60, V61, A64, P76, T77, M79, G89, P99, S109 |
Figure 6Hypothetical depiction of the adverse effects of AGEs on muscle in diabetes and the inhibition of these effects by dietary curcumin or gingerol supplementation.